Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.75 |
| ▸ | HTR1A | P08908 | 6/20 | 0.74 |
| ▸ | HTR7 | P34969 | 4/20 | 0.74 |
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | DRD5 | P21918 | 1/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8045431 | 0.94 | KCNH2 (0.69) | KCNH2HTR1AHTR7DRD2HTR2A | |
| SCHEMBL11247532 | 0.89 | KCNH2 (0.73) | KCNH2HTR1AHTR7DRD2HTR2A | |
| SCHEMBL11260878 | 0.89 | KCNH2 (0.73) | KCNH2HTR1AHTR7DRD2HTR2A | |
| SCHEMBL2114983 | 0.87 | HTR1A (0.73) | KCNH2HTR1AHTR7DRD2HTR2A | |
| SCHEMBL4528457 | 0.87 | KCNH2 (1.00) | KCNH2HTR1AHTR7DRD2HTR2A | |
| SCHEMBL7270516 | 0.86 | HTR1A (0.72) | KCNH2HTR1AHTR7DRD2HTR2A | |
| SCHEMBL1706541 | 0.86 | KCNH2 (0.79) | KCNH2HTR1AHTR7DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL9811592 | 0.85 | HTR1A (0.71) | KCNH2HTR1AHTR7DRD2HTR2A | |
| SCHEMBL11756285 | 0.85 | HTR1A (0.70) | KCNH2HTR1AHTR7DRD2HTR2A | |
| SCHEMBL1085753 | 0.84 | HTR1A (0.65) | KCNH2HTR1AHTR7DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | KCNH2 943/4885HTR1A 114/4885HTR7 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.